|
|
News Breaks | | | | January 30, 2013 | | 07:48 EDT |  | ABBV | AbbVie sees FY13 EPS $3.03-$3.13, consensus $3.08
| |
|
News For ABBV From The Last 14 Days Check below for free stories on ABBV the last two weeks. |
|
|
| June 17, 2013 | | 08:17 EDT |  | ABBV | AbbVie announces preliminary results in Phase 1 study of ABT-199
 Subscribe for More Information | | | June 13, 2013 | | 05:14 EDT | | ABBV | AbbVie presents first study of MTX when used with Humira for RA treatment
AbbVie announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate, or MTX, in combination with Humira for the treatment of moderate to severe rheumatoid arthritis, or RA. CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label Humira. Results were presented at the European League Against Rheumatism 2013 Congress in Madrid, Spain. The primary objective of CONCERTO was to determine a dose-response pattern of MTX in combination with Humira in MTX and biologic-naive patients with active moderate to severe RA for less than 1 year. Patients were randomized into four treatment arms, receiving 40 mg of open-label Humira every other week in combination with weekly oral MTX at 2.5 mg, 5 mg, 10 mg or 20 mg. | | | June 10, 2013 | | 07:40 EDT |  | ABBV | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | June 4, 2013 | | 07:28 EDT | | ABBV | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | |
|
|
|
|
|
|
